SEC Filing Analysis: Monogram Technologies Inc. (MGRM)

Executive Summary

• Trading Significance: High
• Key Takeaway: A director's entire holding of 8,000 stock options was disposed of as a direct result of the company's merger with Zimmer Biomet Holdings, Inc. The options were cancelled and converted into a right to receive cash and Contingent Value Rights (CVRs).
• Market Impact: This transaction is a procedural part of a major corporate action (a merger) and does not reflect a discretionary investment decision by the insider. The market impact is tied to the merger itself, not this specific disposition, which is an expected consequence of the acquisition.

Company Information

Field	Value
Company	Monogram Technologies Inc.
Ticker Symbol	MGRM
CIK	0001769759
Industry	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]

Insider Information

Field	Value
Name	Gray Colleen
CIK	0002091035
Title/Position	null
Relationship	Director

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-10-07
Transaction Code	D (Disposition to the issuer)
Security Type	Stock Option
Shares Involved	8,000
Price Per Share	null
Total Value	null
Shares Owned After	0
Ownership Type	Direct

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: This is not an open-market transaction. It is a mandatory disposition of derivative securities as stipulated by a merger agreement. Therefore, it provides no new signal about the company's future prospects beyond what is already known about the acquisition by Zimmer Biomet.

Volume & Sentiment

• Expected Volume Impact: None. The transaction did not occur on the open market.
• Sentiment Indicator: Neutral. The filing is informational regarding the mechanics of the merger and does not carry a bullish or bearish sentiment from the insider.

Investment Insights

Positive Market Indicators

• The transaction confirms the progression of the previously announced merger, which could be seen as a positive for shareholders receiving the merger consideration.

Risk Factors

• The disposition signifies the end of Monogram Technologies as an independent publicly traded entity, eliminating future upside potential for its shareholders beyond the merger consideration (cash + CVRs).

Key Takeaways

1. Merger-Driven Transaction: The disposition of 8,000 stock options by Director Colleen Gray was a non-discretionary action required by the merger agreement with Zimmer Biomet.
2. Conversion to Cash and CVRs: The options were not sold but were cancelled and converted into a right to receive a combination of cash (the excess of $4.04 over the option's exercise price) and one Contingent Value Right (CVR).
3. Zero Holdings Post-Transaction: The director now holds zero derivative securities of this type, which is expected as the company becomes a wholly owned subsidiary of the acquirer.

Contextual Analysis

Timing Significance

• The transaction date of October 7, 2025, marks the "Effective Time" of the merger, as detailed in the filing's footnotes. The filing on October 14 is a timely report of this event.

Transaction Context

• Footnotes 1 and 2 are critical. They explicitly state the transaction is in connection with the Agreement and Plan of Merger with Zimmer Biomet. The options were cancelled and converted into a right to receive merger consideration. The value received depends on the original exercise price of the options, which is not disclosed, hence the total value cannot be calculated.

Company Context

• Monogram Technologies Inc. is being acquired by Zimmer Biomet Holdings, Inc. This filing is one of many procedural steps in finalizing the acquisition and delisting MGRM stock. All outstanding equity and derivatives are being settled according to the terms of the merger.

Risk Assessment

Risk Level: Low

Risk Factors

• This specific filing poses no new risk to the market. The primary event is the merger, and its associated risks and rewards have been previously disclosed.
• The value of the CVRs received by the insider is contingent and not guaranteed, representing a future risk/reward element tied to post-merger performance milestones.

Market Considerations

• Investors should focus on the terms of the merger agreement for valuation, not this insider filing.
• The event marks the end of public trading for MGRM, and shareholder value is now locked into the merger consideration.

---

IMPORTANT DISCLAIMER: This analysis is for informational purposes only and is not intended as investment advice. The information presented is based on publicly available SEC filings and should not be construed as a recommendation to buy, sell, or hold any securities. Past performance does not guarantee future results. All investments carry risk, including the potential loss of principal. Please consult with a qualified financial advisor before making any investment decisions.

Analysis generated on 2025-10-14 | Data source: SEC EDGAR